Latest News

Comparative Risk Project.  One proposed way to prioritize environmental problems -- and develop viable solutions -- is through "comparative risk assessment."

OEHHA has provided a number of comments on the exposure assessment methodology and conclusions on the draft EAD for Fenoxaprop Ethyl. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Fenoxaprop Ethyl . These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Molinate. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Mevinphos. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Hydrogen Cyanamide. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

This final statement of reasons sets forth the reasons for the repeal of Section 12713 (Exposure to Foods, Drugs, Cosmetics, and Medical Devices) and the amendment to Section 12701 (General), and responds to the objections and recommendations submitted regarding these actions. 

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Cycloate. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Paclobutrazol. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in the attachment.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Abamectin. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in the attachment.